drugset

drugset / Trial / NCT06978725

A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

NCT06978725 ↗

Phase 2 Recruiting 28 enrolled Priovant Therapeutics, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

Timeline

Start: 2025-04-09
Primary completion: 2026-12
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brepocitinib	Small molecule	—	—

Indications